BioVex Limited
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, BioVex Limited sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
BioVex Limited: 5 sponsored US clinical trials, none currently recruiting.
BioVex Limited sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 2 trials.
Upper-quartile sponsor footprint
BioVex Limited sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
NCT01161498
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
NCT01368276
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
NCT00769704
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
NCT00402025
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
NCT00289016
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Therapeutic Areas
How the BioVex Limited archive is shaped
5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Melanoma (2 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
BioVex Limited: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
BioVex Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this BioVex Limited page
5 registered trials is a research-attention snapshot, not an endorsement of BioVex Limited or any single study.
- None of BioVex Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Melanoma is the condition BioVex Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioVex Limited pipeline card: 5 registered trials from official public datasets.Report a data error.